The sigma-1 receptor, a protein found in the central nervous system and immune cells, can be activated by the psychedelic compounds N,N-dimethyltryptamine (NN-DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) to dampen inflammatory responses in human immune cells. When human dendritic cells were exposed to inflammatory triggers along with these compounds, production of pro-inflammatory cytokines IL-1β, IL-6, TNFα, and chemokine IL-8 decreased, while the anti-inflammatory cytokine IL-10 increased. The compounds also reduced the cells' ability to activate inflammatory T-cells. This suggests dimethyltryptamines may act as endogenous regulators of inflammation and immune balance, pointing toward potential treatments for autoimmune and chronic inflammatory conditions.
Ischemia-reperfusion injury (IRI) arises from disrupted blood flow and subsequent restoration, causing damage in emergency medicine. Mitochondrial and endoplasmic reticulum dysfunction are key factors. The sigma-1 receptor (Sig1-R), a chaperone between these organelles, regulates signaling and protects against cellular stress. Activating Sig1-R improves mitochondrial respiration and endoplasmic reticulum function. N, N-dimethyltryptamine (DMT), an endogenous Sig1-R agonist, may have therapeutic potential. This article reviews Sig1-R's role in cellular bioenergetics and IRI, summarizing in vitro and in vivo DMT studies. The authors conclude DMT may universally protect cells, suggesting therapies for IRI in brain ischemia after stroke or cardiac arrest.